Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextrose + levobupivacaine is a combination formulation used primarily for spinal (intrathecal) anesthesia. Levobupivacaine is the S-enantiomer of bupivacaine, an amide-type local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, inhibiting nerve impulse conduction and producing loss of sensation and motor function in the area supplied by the affected nerves. Dextrose is added to make the solution hyperbaric, which allows for more predictable spread within the cerebrospinal fluid based on patient positioning. This combination is used to achieve rapid onset and prolonged duration of sensory block with reduced motor blockade compared to racemic bupivacaine or other local anesthetics. The addition of dextrose does not alter the mechanism of action but modifies physical properties (density/baricity) for clinical effect[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextrose + levobupivacaine.